WebSep 20, 2005 · Brief Summary: The study evaluates the efficacy and tolerability of a dose-reduced chemotherapy for the treatment of elderly patients with acute lymphoblastic leukemia. In patients with expression of CD20 on leukemic cells the efficacy and tolerability of additional application of Rituximab together with chemotherapy is evaluated. Study … WebMar 9, 2024 · Inotuzumab ozogamicin (PF-05208773; CMC-544) is an antibody-targeted intravenous (IV) chemotherapy agent composed of an anti-CD22 antibody linked to calicheamicin, a potent cytotoxic antitumor antibiotic. After a prephase treatment, induction therapy will be based on three cycles of inotuzumab ozogamicin and intrathecal therapy …
UpToDate
WebJan 19, 2024 · Stelljes M. Inotuzumab ozogamicin induction followed by standard chemotherapy yields high remission rates and promising survival in older (>55 Years) patients with de novo B-lymphoblastic leukemia (GMALL-Initial1 Trial). Oral abstract #212. 64th American Society of Hematology Annual Meeting and Exposition; Dec 10, 2024; … biw online course
Adult ALL: treatment outcome and prognostic factors in an Indian ...
WebMar 9, 2024 · Inotuzumab ozogamicin (PF-05208773; CMC-544) is an antibody-targeted intravenous (IV) chemotherapy agent composed of an anti-CD22 antibody linked to … WebSixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al. [15]. The complete remission … WebAug 23, 2024 · The induction chemotherapy for adults with newly diagnosed ALL is reviewed here. The following related subjects are discussed separately: ... Analysis of More Than 1200 Patients from GMALL Data Bases. Blood (ASH Annual Meeting Abstracts) 2024; 132. Gökbuget N. How I treat older patients with ALL. Blood 2013; 122:1366. dateline idaho murder how to watch